Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Seelos Therapeutics, Inc. - Common Stock
(NQ:
SEEL
)
1.280
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Oct 15, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Seelos Therapeutics, Inc. - Common Stock
< Previous
1
2
...
13
14
15
16
17
18
19
20
Next >
Mid-Afternoon Market Update: Dow Gains 150 Points; Red Cat Holdings Shares Spike Higher
↗
September 27, 2021
Toward the end of trading Monday, the Dow traded up 0.43% to 34,949.08 while the NASDAQ fell 0.35% to 14,995.27. The S&P also fell, dropping 0.05% to 4,453.40. The U.S. has...
Via
Benzinga
Topics
Stocks
Why Seelos Therapeutics Stock Is Trading Higher Today
↗
September 27, 2021
Seelos Therapeutics Inc (NASDAQ:SEEl) is trading higher Monday after Roth Capital analyst Jonathan Aschoff upgraded the stock from Neutral to Buy and raised the price...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
↗
September 27, 2021
Gainers Keros Therapeutics (NASDAQ:KROS) stock moved upwards by 26.51% to $41.75 during Monday's regular session. Keros Therapeutics's stock is trading at a volume...
Via
Benzinga
31 Stocks Moving In Monday's Mid-Day Session
↗
September 27, 2021
Gainers Red Cat Holdings, Inc. (NASDAQ: RCAT) shares jumped 54.1% to $3.6998 after the company said its subsidiary, Skypersonic, Inc, won a five-year contract from NASA to...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 27, 2021
↗
September 27, 2021
Upgrades According to Roth Capital, the prior rating for Seelos Therapeutics Inc (NASDAQ:
Via
Benzinga
Seelos Therapeutics Shares Gain On FDA Approval To Add SLS-005 Regimen In HEALEY ALS Trial
↗
September 21, 2021
The Sean M. Healey & AMG Center for ALS at Mass General received approval from the FDA and the Mass General Brigham Institutional Review Board to add SLS-005 (...
Via
Benzinga
Why Seelos Therapeutics' Stock Is Trading Higher Today
↗
September 21, 2021
Seelos Therapeutics (NASDAQ:SEEL) shares are trading higher. Traders are circulating a Massachusetts General Hospital report titled 'Investigational drug SLS-005 (...
Via
Benzinga
$10 Billion Sackler Opioid Settlement Closes Chapter, Psychedelic Chapter Begins
September 15, 2021
Via
FinancialNewsMedia
Psychedelic Medicine's Top CEOs: Who's Running The Biggest Companies In This Booming Industry?
↗
September 09, 2021
By Natan Ponieman and Javier Hasse The psychedelic medicine industry is growing by leaps and bounds. Leading this charge is a group of ambitious and visionary corporate...
Via
Benzinga
Psychedelic Drug Industry Report Card For 2021
↗
September 01, 2021
In assessing the psychedelic drug industry, a primary focus for investors is drug development.
Via
Talk Markets
25 Stocks Moving in Monday's Pre-Market Session
↗
August 23, 2021
Gainers Greenpro Capital Corp. (NASDAQ: GRNQ) rose 48.7% to $1.13 in pre-market trading. Greenpro Capital shares gained 16% on Friday after the company announced its Angkasa-X...
Via
Benzinga
Which Psychedelic Drug Stock Category Outperformed Last Week
↗
August 10, 2021
Which has performed best YTD, the Pure-Play Marijuana Drug Stocks Index or the Pure-Play Psychedelic Compounds-Based Drug Stocks Index?
Via
Talk Markets
Topics
Cannabis
Field Trip Health Heads To The Nasdaq As Wall Street Opens Up To "Psychedelics Renaissance"
↗
July 23, 2021
Excitement around psychedelics grows as major U.S. exchanges make room for more companies in the sector. On Friday,
Via
Benzinga
Psychedelics Gain More Traction as New Research Aims to Address Chronic Pain and Mental Illness
July 21, 2021
Via
FinancialNewsMedia
Topics
Law Enforcement
How To Invest In "Magic Mushrooms" (Psychedelics)
↗
July 09, 2021
A look at psychedelics as stock market investment opportunities and identifying alternative strategies on how to invest.
Via
Talk Markets
Psychedelics Research FYI: Every Clinical Trial Underway Right Now Involving Public And Private Companies
↗
July 07, 2021
This article was made possible thanks to invaluable research by Michael Haichin and Josh Hardman from Ps...
Via
Benzinga
Seelos' Single Dose Of SLS-004 Shows Reduction In Parkinson's Associated mRNA, Protein Expression
↗
July 07, 2021
Seelos Therapeutics Inc (NASDAQ: SEEL) has announced positive in vivo data demonstrating down-regulation of SNCA mRNA and protein expression from a study of SLS-...
Via
Benzinga
The Daily Biotech Pulse: Opiant Spikes On Data, OncoSec Rallies On Merck Collaboration, XBiotech Special Dividend
↗
July 07, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 6) Ambrx Biopharma Inc. (NYSE:...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
July 06, 2021
Gainers Opiant Pharmaceuticals (NASDAQ:OPNT
Via
Benzinga
Why Seelos Therapeutics Is Moving Today
↗
July 01, 2021
Seelos Therapeutics, Inc. (NASDAQ: SEEL) shares are trading higher after Guggenheim analyst Yatin Suneja initiated coverage on the stock with a Buy rating and announced an $8...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 1, 2021
↗
July 01, 2021
Upgrades Citigroup upgraded the previous rating for Thor Industries Inc (NYSE:
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
July 01, 2021
Gainers Alterity Therapeutics (NASDAQ:ATHE) shares moved upwards by 60.76% to $2.09 during Thursday's pre-market session. The market value of their outstanding shares...
Via
Benzinga
Why Seelos Therapeutics Stock Is Jumping Today
↗
June 01, 2021
The company has been included in the first U.S. psychedelics-focused ETF.
Via
The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For June 1, 2021
↗
June 01, 2021
Upgrades For Equity Residential (NYSE:EQR), BMO Capital upgraded the previous rating of Market Perform to Outperform. Equity Residential earned $0.68 in the first quarter...
Via
Benzinga
Seelos's Amyotrophic Lateral Sclerosis Candidate, SLS-005 An Orphan Drug In Europe
↗
May 27, 2021
Seelos Therapeutics Inc's (NASDAQ: SEEL) Trehalose (SLS-005) has received Orphan Drug Designation for amyotrophic lateral sclerosis (ALS) from the European...
Via
Benzinga
Psyched: MindMed To Begin Mescaline Trials and Deepak Chopra Partnership, Seelos And Cybin Advance Clinical Research
↗
May 24, 2021
MindMed’s News Spree: Mescaline Trials, Chopra Foundation Partnership and LSD Research MindMed (NASDAQ:
Via
Benzinga
Increased R&D Activities Have Fueled Growth and Promise for Pancreatic Cancer Treatment
May 20, 2021
Via
FinancialNewsMedia
Topics
Death
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
May 20, 2021
Gainers VistaGen Therapeutics (NASDAQ:VTGN) shares moved upwards by 14.34% to $2.63 during Thursday's pre-market session. The market value of their outstanding shares...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
↗
May 19, 2021
Gainers VistaGen Therapeutics (NASDAQ:VTGN
Via
Benzinga
CNS Pharmaceuticals Commences Patient Enrollment in Potentially Pivotal Study of Berubicin
↗
May 19, 2021
CNS Pharmaceuticals today announced open enrollment for its potentially pivotal study evaluating the efficacy and safety of Berubicin in the treatment of recurrent GBM.
Via
Talk Markets
< Previous
1
2
...
13
14
15
16
17
18
19
20
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.